What Are the Main Threats to AbbVie's Humira?

AbbVie (NYSE: ABBV  ) , which was spun out of health care stalwart Abbott Laboratories (NYSE: ABT  ) at the start of 2013, has beaten the market -- and its former parent company -- by leaps and bounds this year. It reported solid second-quarter results, largely fueled by 16% year-over-year sales growth of its top-selling autoimmune disease drug, Humira, but are there any threats to AbbVie's most important product? In the following video, from The Motley Fool's health-care show Market Checkup, analysts David Williamson and Max Macaluso review the highlights from AbbVie's second-quarter results, discuss the company's dependence on its high-flying blockbuster drug, and explain potential competitive threats to Humira, such as Pfizer's drug Xeljanz.

AbbVie may be beating the market this year, but Motley Fool co-founder David Gardner, founder of the No. 1 growth stock newsletter in the world, has developed a unique strategy for uncovering truly wealth-changing stock picks. And he wants to share it, along with a few of his favorite growth stock superstars, WITH YOU! It's a special 100% FREE report called "6 Picks for Ultimate Growth." So stop settling for index-hugging gains... and click HERE for instant access to a whole new game plan of stock picks to help power your portfolio.

Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 09, 2013, at 2:39 PM, boczernyk wrote:

    Good, balanced talk on AbbVie. Unlike many HepC stock neophytes, talk was correct re ABBV lead in oral HCV drug development, being head-to-head w Gilead in 2014 non-intereferon therapy rollout.Genotype1 is the largest US patient pool by far, s/b enough for both cos. A high-growth biotech, w 3.8%dividend.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2628522, ~/Articles/ArticleHandler.aspx, 6/30/2016 2:00:49 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 17,877.84 183.16 1.04%
S&P 500 2,091.29 20.52 0.99%
NASD 4,821.87 42.62 0.89%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

6/30/2016 1:44 PM
ABT $39.11 Up +0.54 +1.40%
Abbott Laboratorie… CAPS Rating: *****
AMGN $152.00 Up +1.90 +1.27%
Amgen CAPS Rating: *****
AZN $30.13 Up +0.28 +0.93%
AstraZeneca CAPS Rating: ****
CELG $98.72 Down -0.10 -0.10%
Celgene CAPS Rating: *****
JNJ $120.85 Up +1.52 +1.27%
Johnson and Johnso… CAPS Rating: *****
PFE $35.10 Up +0.09 +0.26%
Pfizer CAPS Rating: ****
REGN $347.74 Down -0.12 -0.03%
Regeneron Pharmace… CAPS Rating: ***